OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS Share Price
Certificat
DE000SF7UWJ0
| Market Closed - Deutsche Boerse AG 01:14:47 01/06/2024 am IST | ||
| 24.29 EUR | +5.84% |
|
| Current month | +27.31% | ||
| 1 month | +27.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 24.29 | +5.84% |
| 30/24/30 | 22.95 | -1.08% |
| 29/24/29 | 23.2 | -1.11% |
| 28/24/28 | 23.46 | -4.17% |
| 27/24/27 | 24.48 | +0.45% |
Delayed Quote Deutsche Boerse AG
Last update May 01, 2024 at 01:14 am IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SF7UWJ |
| ISIN | DE000SF7UWJ0 |
| Date issued | 18/08/2021 |
| Strike | 192 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.67 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 24.52 € |
|---|---|
| Lowest since issue | 1.63 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Certificates
- Certificat
